# Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

> **NCT05266846** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 78 (estimated)

## Conditions studied

- ALK Gene Mutation
- Lung Adenocarcinoma
- Immunotherapy

## Interventions

- **DRUG:** Pembrolizumab injection

## Key facts

- **NCT ID:** NCT05266846
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2026-11-16
- **Final completion:** 2027-02-16
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266846, "Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05266846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*